AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24604881 — intervention group
Group type: COMPARATOR
Intervention: No depression (PHQ-9 <5)
Number of subjects: 1418
Study 22367128 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal stabilization exercises (SSE)
Number of subjects: 21
Study 22367128 — intervention group
Group type: COMPARATOR
Intervention: Control exercise program
Number of subjects: 21
Study 18952211 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil breakfast
Number of subjects: 20
Study 18952211 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut breakfast
Number of subjects: 20
Study 18952211 — intervention group
Group type: COMPARATOR
Intervention: Butter breakfast
Number of subjects: 20
Study 21036889 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 4217
Study 15827910 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (PT) and medication therapy (MT) for the first 6 weeks, followed by MT only for the second 6 weeks.
Number of subjects: 68
Study 15827910 — intervention group
Group type: COMPARATOR
Intervention: PT and MT for the second 6 weeks after receiving only MT for the first 6 weeks.
Number of subjects: 68
Study 15827910 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (PT) and medication therapy (MT) for the second 6 weeks after receiving only MT for the first 6 weeks.
Number of subjects: 68
Study 12350390 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) as adjunctive therapy, initiated at 0.5-1 mg/kg, titrated to a maximum of 12 mg/kg over a mean treatment period of 15.8 months (range 3-98 months).
Number of subjects: 45
Study 12350390 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) as adjunctive therapy.
Number of subjects: 45
Study 10611054 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alfa-2b plus ribavirin for 24 or 48 weeks
Number of subjects: 1773
Study 10611054 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD, Caelyx(R))
Number of subjects: 1773
Study 10611054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis of PLD
Number of subjects: 1773
Study 8952810 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 1.5 mg sustained-release form
Number of subjects: 690
Study 8952810 — intervention group
Group type: COMPARATOR
Intervention: Indapamide 2.5 mg immediate-release form
Number of subjects: 690
Study 1935254 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 percent topical minoxidil
Number of subjects: 28
Study 1935254 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 28
Study 6282106 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium
Number of subjects: 6
Study 6282106 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose
Number of subjects: 6
Study 6282106 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectin
Number of subjects: 6
Study 29866165 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula therapy (HFNC)
Number of subjects: 121
Study 29866165 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 121
Study 27371105 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 25025854 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic calcium sulfate (CS)
Number of subjects: 10
Study 25025854 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic calcium sulfate (CS) in combination with gamma‐radiated human mineralized allograft
Number of subjects: 10
Study 22906960 — intervention group
Group type: EXPERIMENTAL
Intervention: Sudden weaning from NCPAP
Number of subjects: 56
Study 22906960 — intervention group
Group type: COMPARATOR
Intervention: Gradual weaning from NCPAP
Number of subjects: 56
Study 20801567 — intervention group
Group type: EXPERIMENTAL
Intervention: Each 2-kg/m(2) increase in BMI
Number of subjects: 652
Study 18343262 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER (3-12 mg)
Number of subjects: 0
Study 18343262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18343262 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Number of subjects: 0
Study 18343262 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER (3, 6, 9, 12, 15 mg/d)
Number of subjects: 0
Study 15994396 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrostomy
Number of subjects: 41
Study 15994396 — intervention group
Group type: COMPARATOR
Intervention: Nasogastric tube (Control)
Number of subjects: 41
Study 12734745 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine suspension
Number of subjects: 20
Study 12734745 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine tablets
Number of subjects: 20
Study 10411029 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic implantation of self-expanding permanent endoluminal stents (Wallstent, Memotherm stent, Sinus stent)
Number of subjects: 13
Study 8739863 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole-D (10 mg astemizole and 240 mg pseudoephedrine)
Number of subjects: 64
Study 8739863 — intervention group
Group type: COMPARATOR
Intervention: Brompheniramine-D (12 mg brompheniramine and 50 mg phenylpropanolamine)
Number of subjects: 64
Study 1911497 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg epidural morphine
Number of subjects: 108
Study 1911497 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg epidural morphine and 100 micrograms fentanyl
Number of subjects: 108
Study 6789205 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal-intensive-care programs
Number of subjects: 0
Study 6789205 — intervention group
Group type: COMPARATOR
Intervention: Individual interventions within neonatal intensive care
Number of subjects: 0
Study 29521885 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone-present with use encouraged
Number of subjects: 148
Study 29521885 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone-present with use restricted
Number of subjects: 148
Study 29521885 — intervention group
Group type: COMPARATOR
Intervention: No phone access
Number of subjects: 148
Study 29521885 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol responses
Number of subjects: 148
Study 27626136 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Monitoring
Number of subjects: 1643
Study 27626136 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 1643
Study 27626136 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 1643
Study 24438744 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium 50 μg once daily
Number of subjects: 657
Study 24438744 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium 18 μg once daily
Number of subjects: 657
Study 22425041 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on a urethrovesical model
Number of subjects: 28
Study 22425041 — intervention group
Group type: COMPARATOR
Intervention: Basic laparoscopic suturing and knot tying on foam pads
Number of subjects: 28
Study 21162825 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting capillary blood glucose cut-off value of 6.0 mmol/L for undiagnosed diabetes mellitus
Number of subjects: 3250
Study 21162825 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting capillary blood glucose cut-off value of 5.7 mmol/L for impaired fasting glucose (IFG)
Number of subjects: 3250
Study 21162825 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting capillary blood glucose cut-off value of 5.7 mmol/L for impaired glucose tolerance (IGT)
Number of subjects: 3250
Study 17764477 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional cigarettes (FTC tar 11 mg; CC1)
Number of subjects: 3
Study 17764477 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional cigarettes (FTC tar 6 mg; CC2)
Number of subjects: 3
Study 17764477 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette switch (FTC tar 1 mg; CC3)
Number of subjects: 3
Study 17764477 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop smoking
Number of subjects: 3
Study 15564721 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (anti-CD20 antibody), administered in up to 4 treatment cycles, possibly in combination with corticosteroid, cyclophosphamide, and/or methotrexate.
Number of subjects: 40
Study 15564721 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (anti-CD20 antibody)
Number of subjects: 40
Study 11953726 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin (80-100 mg/kg/day)
Number of subjects: 209
Study 11953726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 9876550 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (generic preparation)
Number of subjects: 12
Study 9876550 — intervention group
Group type: COMPARATOR
Intervention: Betaloc (innovator product)
Number of subjects: 12
Study 8747407 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg)
Number of subjects: 160
Study 2233115 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 90 mg twice daily
Number of subjects: 40
Study 2233115 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine 10 mg three times daily
Number of subjects: 40
Study 401521 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin alone
Number of subjects: 71
Study 401521 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin plus gentamicin
Number of subjects: 71
Study 401521 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin alone
Number of subjects: 71
Study 401521 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin
Number of subjects: 71
Study 31678947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 31678947 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise 150 min/week + Placebo
Number of subjects: 200
Study 31678947 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg/day
Number of subjects: 200
Study 31678947 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise 150 min/week + Liraglutide 3.0 mg/day
Number of subjects: 200
Study 28143414 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrushing plus 0.12% chlorhexidine gel
Number of subjects: 213
Study 28143414 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine solution 0.12% without toothbrushing
Number of subjects: 213
Study 26291873 — intervention group
Group type: EXPERIMENTAL
Intervention: Soothing liver and regulating mind group
Number of subjects: 163
Study 26291873 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint shallow puncturing group
Number of subjects: 163
Study 26291873 — intervention group
Group type: COMPARATOR
Intervention: Non-acupoint shallow puncturing group
Number of subjects: 163
Study 19262364 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0
Study 19262364 — intervention group
Group type: COMPARATOR
Intervention: Control (no paroxetine)
Number of subjects: 0
Study 21208101 — intervention group
Group type: EXPERIMENTAL
Intervention: Iniparib plus gemcitabine and carboplatin
Number of subjects: 123
Study 21208101 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine and carboplatin (control)
Number of subjects: 123
Study 18172769 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug Court with usual community‐based treatment (DC)
Number of subjects: 0
Study 18172769 — intervention group
Group type: EXPERIMENTAL
Intervention: DC with Multisystemic Therapy (DC/MST)
Number of subjects: 0
Study 18172769 — intervention group
Group type: EXPERIMENTAL
Intervention: DC/MST enhanced with Contingency Management (DC/MST/CM)
Number of subjects: 0
Study 18172769 — intervention group
Group type: COMPARATOR
Intervention: Family Court with usual community‐based treatment (FC)
Number of subjects: 0
Study 17926489 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronotherapy with monocinque
Number of subjects: 65
Study 17926489 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex treatment with monocinque and melatonin
Number of subjects: 65
Study 17926489 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy with monocinque
Number of subjects: 65
Study 15226683 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacerein
Number of subjects: 0
Study 11137278 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard referral with an incentive
Number of subjects: 196
Study 11137278 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff escort from detoxification to aftercare with an incentive
Number of subjects: 196
Study 11137278 — intervention group
Group type: COMPARATOR
Intervention: Standard referral
Number of subjects: 196
Study 9684909 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (120 mg ZnSO4 after each dialysis session)
Number of subjects: 26
Study 9684909 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group II)
Number of subjects: 26
Study 9684909 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (HS) (Group III)
Number of subjects: 26
Study 7851362 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH-FAT diet (70% fat, 7% CHO)
Number of subjects: 5
Study 7851362 — intervention group
Group type: COMPARATOR
Intervention: HIGH-CHO diet (74% CHO, 12% fat)
Number of subjects: 5
Study 7851362 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH-FAT diet
Number of subjects: 5
Study 7851362 — intervention group
Group type: COMPARATOR
Intervention: HIGH-CHO diet
Number of subjects: 5
Study 2670447 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 IU of heparin (subcutaneously, twice daily) for 14 to 21 days
Number of subjects: 103
Study 2670447 — intervention group
Group type: COMPARATOR
Intervention: Control group without anticoagulant prophylaxis
Number of subjects: 103
Study 1158003 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% nickel sulfate and 0.1% triamcinolone acetonide in petrolatum
Number of subjects: 15
Study 1158003 — intervention group
Group type: COMPARATOR
Intervention: 5% nickel sulfate in petrolatum
Number of subjects: 15
Study 1158003 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide infiltration
Number of subjects: 15
Study 1158003 — intervention group
Group type: COMPARATOR
Intervention: Saline solution infiltration
Number of subjects: 15
Study 1158003 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% triamcinolone acetonide cream
Number of subjects: 15
Study 1158003 — intervention group
Group type: COMPARATOR
Intervention: Cream base alone
Number of subjects: 15
Study 31226684 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical disc arthroplasty (CDA) using Prestige LP Cervical Disc
Number of subjects: 209
Study 31226684 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 209
Study 31226684 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical disc arthroplasty (CDA)
Number of subjects: 209
Study 29157765 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich drink (CHD)
Number of subjects: 90
Study 29157765 — intervention group
Group type: COMPARATOR
Intervention: 5% glucose intravenous infusion
Number of subjects: 90
Study 29157765 — intervention group
Group type: COMPARATOR
Intervention: Fasting from midnight
Number of subjects: 90
Study 25951426 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.03% ointment
Number of subjects: 41
Study 25951426 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide 0.1% cream
Number of subjects: 41
Study 23731186 — intervention group
Group type: EXPERIMENTAL
Intervention: Respondent-driven sampling (RDS)
Number of subjects: 0
Study 23731186 — intervention group
Group type: COMPARATOR
Intervention: General practice (GP) recruitment
Number of subjects: 0
Study 21219504 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral swab test
Number of subjects: 32
Study 21219504 — intervention group
Group type: COMPARATOR
Intervention: Blood test
Number of subjects: 32
Study 20035588 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 83
Study 20035588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 16275661 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control
Number of subjects: 266
Study 16275661 — intervention group
Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 266
Study 12421482 — intervention group
Group type: EXPERIMENTAL
Intervention: Pollen extract EA-10, P5
Number of subjects: 0
Study 12421482 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 10530656 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 91
Study 10530656 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 91
Study 7854376 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (200 mg per day)
Number of subjects: 428
Study 7854376 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole troches (10 mg taken five times daily)
Number of subjects: 428
Study 7854376 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 428
Study 7854376 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole and Clotrimazole
Number of subjects: 428
Study 1941832 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin (AF) at a dosage of 0.15‐0.2 mg/kg/day (9 mg/day maximum)
Number of subjects: 88
Study 1941832 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin (AF)
Number of subjects: 88
Study 7048825 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximate stapler
Number of subjects: 137
Study 7048825 — intervention group
Group type: COMPARATOR
Intervention: Conventional skin closure
Number of subjects: 137
Study 6704012 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical indomethacin
Number of subjects: 0
Study 6704012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6704012 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgically treated eyes
Number of subjects: 0
Study 30082137 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal parathyroidectomy
Number of subjects: 69
Study 30082137 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parathyroidectomy with autotransplantation of 45 fragments
Number of subjects: 69
Study 30082137 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parathyroidectomy with autotransplantation of 90 fragments
Number of subjects: 69
Study 26851189 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld lights (with or without polarizing filter)
Number of subjects: 96
Study 26851189 — intervention group
Group type: COMPARATOR
Intervention: Viewing booth
Number of subjects: 96
Study 26851189 — intervention group
Group type: COMPARATOR
Intervention: Before sessions using viewing booth
Number of subjects: 96
Study 26851189 — intervention group
Group type: EXPERIMENTAL
Intervention: After sessions using handheld lights
Number of subjects: 96
Study 26851189 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and training
Number of subjects: 96
Study 26851189 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined effect of light and education/training
Number of subjects: 96
Study 24769601 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean Immigrants and Mammography‐Culture‐Specific Health Intervention (KIM‐CHI) program (n = 211 couples)
Number of subjects: 428
Study 24769601 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (n = 217 couples)
Number of subjects: 428
Study 22549295 — intervention group
Group type: EXPERIMENTAL
Intervention: PEA-based optimization of CRT
Number of subjects: 268
Study 22549295 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard methods)
Number of subjects: 268
Study 19736051 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol and simethicone solution (2l) 16h before VCE
Number of subjects: 60
Study 19736051 — intervention group
Group type: COMPARATOR
Intervention: Fibre-free diet and clear liquids the day before VCE
Number of subjects: 60
Study 18569948 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone prophylaxis
Number of subjects: 0
Study 15793647 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation
Number of subjects: 4
Study 12090863 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/d of conjugated estrogens plus 2.5 mg of medroxyprogesterone acetate
Number of subjects: 2763
Study 12090863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2763
Study 10628058 — intervention group
Group type: EXPERIMENTAL
Intervention: Health checks
Number of subjects: 1371
Study 8750399 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular meloxicam (15 mg)
Number of subjects: 113
Study 8750399 — intervention group
Group type: COMPARATOR
Intervention: Oral meloxicam (15 mg)
Number of subjects: 113
Study 2040038 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone (120 mg i.v. repeated after 4 hours) + metoclopramide (0.5 mg/kg i.v. bolus over 30 min + 1 mg/kg continuous infusion over 24 h) + alprazolam (0.5 mg p.o.)
Number of subjects: 30
Study 2040038 — intervention group
Group type: COMPARATOR
Intervention: Conventional antiemetic regimen (metoclopramide + alprazolam) without high-dose methylprednisolone
Number of subjects: 30
Study 6452794 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine 100 mg b.i.d.
Number of subjects: 40
Study 6452794 — intervention group
Group type: COMPARATOR
Intervention: Desipramine 75 mg b.i.d.
Number of subjects: 40
Study 31107793 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral feeding intervention (n=12)
Number of subjects: 16
Study 31107793 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=12)
Number of subjects: 16
Study 31107793 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study 29071370 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% hypobaric bupivacaine USpA
Number of subjects: 60
Study 29071370 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% hypobaric ropivacaine USpA
Number of subjects: 60
Study 24915175 — intervention group
Group type: EXPERIMENTAL
Intervention: Saffron (300 mg/d)
Number of subjects: 39
Study 24915175 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (75 mg, 25 mg thrice a day)
Number of subjects: 39
Study 24915175 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 39
Study 23809501 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist initiation on cycle day 2
Number of subjects: 160
Study 23809501 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist initiation on cycle day 6 (control)
Number of subjects: 160